fda-authorizes-first-next-generation-sequence-test-for-diagnosing-covid-19
5
FDA Authorizes First Next Generation Sequence Test for Diagnosing COVID-19
FDA Authorizes First Next Generation Sequence Test for Diagnosing COVID-19
Last Reviewed : 01/05/2021
Press Release:
The U.S. Food and Drug Administration issued an emergency use authorization (EUA) to Illumina, Inc. for the first COVID-19 diagnostic test utilizing next generation sequence technology. The FDA authorized the Illumina COVIDSeq Test for the qualitative detection of SARS-CoV-2 RNA from respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider. Using next generation sequencing means that the test can generate information about the genomic sequence of the virus present in a sample, which can be also used for research purposes.
Next generation sequencing is a type of diagnostic technology that can determine, among other things, the genetic sequence of a virus. Comparing sequencing results over time can help scientists understand if and how viruses mutate.
Source: U.S. Food and Drug Administration.
